Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$NMXS News: Net Medical Begins Covid Testing on Behalf of New Mexico Department of Health
Leaning on two decades of experience connecting providers with the patients who need them, Net Medical's business is unique and growing.
ALBUQUERQUE, NM / ACCESSWIRE / February 7, 2022 / Net Medical Xpress Solutions (OTC PINK:NMXS) announced today it has begun Covid testing under an agreement with the State of New Mexico Department of Health.
Under the terms of the agreement, NMXS is:
Providing both rapid antigen and PCR tests at a variety of sites.
Providing a licensed physician for Covid testing.
Providing CLIA (Clinical Laboratory Improvement Amendments) certified laboratory facilities to process and analyze test specimens.
Staffing and equipping a project management hub, laboratory, and mobile testing units with a capacity of 700 persons to be tested per day.
Providing fully equipped mobile testing teams with a minimum of two persons per team for the region.
Providing a copy of certified results from our CLIA certification to each person tested.
Net Medical Chief Medical Officer (CMO) Dr. Neeraj Dubey, MD said, "We are delighted to be providing COVID testing services for the state of New Mexico. Our mobile testing vans are operating successfully in Albuquerque and Taos. This is an important activity for our company and, ultimately, for our shareholders as it is already contributing to increases in revenue and cash flow."
Net Medical is providing COVID-19 testing at Wilson Stadium in Albuquerque in cooperation with Albuquerque Public Schools and Sagebrush Inn and Suites in Taos as well as other locations.
For more information, call 505-255-1999. X 320. Visit www.netmedical.com. Email ir@netmedical.com
Net Medical partners with state departments of health, healthcare facilities, hospitals and clinics to provide extensive and unique customized solutions for the rapidly expanding multi-billion dollar telemedicine and testing industries. Understanding the complex and evolving needs of serving rural, regional, and high-risk populations, Net Medical has a long legacy of working with healthcare organizations to quickly create solutions that meet their immediate needs:
Providing access to care, keeping patients within hospital walls
Providing complete care, anywhere - without the patient's need to travel
Sustaining and growing revenue to continue viability in serving their communities
About Net Medical Labs, Inc.
Net Medical's proprietary suite of services include Telemed platform, electronic medical records interoperability, state-of-the-art conferencing and communications, a call center, unique hardware implementations, and advanced research and development capabilities. No other telemedicine company offers the same extensive and integrated menu of telemedicine and laboratory services as Net Medical, allowing each healthcare organization the ability to custom-create an integrated solution that works for them.
SOURCE: Net Medical Xpress Solutions, Inc.
View source version on accesswire.com:
https://www.accesswire.com/687018/Net-Medical-Begins-Covid-Testing-on-Behalf-of-New-Mexico-Department-of-Health
How To Be Your Own Corona-COVID Doctor !!
To Save You & Family & Children From Any Virus !
https://investorshub.advfn.com/I-have-or-had-CoronaVirus-COVID19-38361/
Happy Day
.
$NMXS is providing vital testing for Covid-19 in New Mexico which is very much needed at this time. This company is making a significant contribution to combating the ongoing pandemic and saving lives.
From the company website:
Net Medical's unique suite of products and services addresses the unparalleled circumstances our global population faces due to the COVID-19 pandemic.?On-site Testing for your employees or event attendees provides an extra layer of safety at your location. Learn more about our mobile lab.
Click here:
https://www.welcome.netmedical.com/mobile-lab
Achiko CEO says Indonesian-launched COVID-19 Rapid Test "dramatically more accurate" than others.
In an interview with multi-media news platform Proactive, Achiko CEO Steven Goh shares the exciting progress of the Company's DNA aptamer-based COVID-19 rapid test AptameX™ in Indonesia and the plans to bring the test kit to other parts of Asia, the Middle East and northern Africa (MENA), and Europe.
Watch Interview:
2 young people https://www3.nhk.or.jp/nhkworld/en/news/20210829_01/
ORAMED vaccine in pill form.
fully vaxed US citizens returning from abroad, must present negative pcr test prior to boarding an airplane
fool fighters concerts in Alaska only for vaxed. people from Russia with sputnik vaxine can attend
COMMUSCISM was at 0% in the USA ww1, ww2, now we are at 50 %, the next plandemic in 10-12 years will destroy our country, if we dont act now to root them out.
phuking big fat greek MORONS ban music in Heraklion to lower the number of kovid cases
https://news.gtp.gr/2021/08/10/covid-19-curfew-imposed-in-heraklion-crete/
flash the pill up COMMUSCIST police faces in europe when they ask for vax passport
$RLFTF $NRXP “Aviptadil has been granted compassionate care authorization in the United States and Israel and has been granted Emergency Use Authorization in Georgia, Ukraine, and the Caucasus region, as well as India.” INDIA Flag of India GEORGIA Flag of Georgia UKRAINE Flag of Ukraine EUA approved
Updated preprint:
https://privpapers.ssrn.com/sol3/papers.cfm?abstract_id=3830051
ENZOLYTICS (ENZC) Close to a cure for Covid, Aids, and everything else. Uses Artificial Intelligence for its Monoclonal technology to learn how to defeat viruses by exposing then attacking the weak spot of the virus. Has a White Paper with Intel and may be partnering with Pharma distributor Lonza. They are working at Texas A&M university and a few other places.
ENZOLYTICS (ENZC) Close to a cure for Covid, Aids, and everything else. Uses Artificial Intelligence for its Monoclonal technology to learn how to defeat viruses by exposing then attacking the weak spot of the virus. Has a White Paper with Intel and may be partnering with Pharma distributor Lonza. They are working at Texas A&M university and a few other places.
TX Gov. Abbott orders Nat. Guard to arrest illegal immigrants
https://americanmilitarynews.com/2021/07/tx-gov-abbott-orders-nat-guard-to-arrest-illegal-immigrants/
#Covid $WTRH
$IBIO iBio, Inc.“Studies of convalescent sera from patients that have recovered from SARS-CoV-2 infection have shown that the combination of N-directed and S-directed immunity is important,” said Martin Brenner, DVM. Ph.D., iBio’s CSO. “Accordingly, we believe the N protein strategy of IBIO-202 may be complementary with existing S-directed vaccines, conferring additional protective effects that more closely mimic the natural immune responses of patients that have cleared the virus.”
https://finance.yahoo.com/news/ibio-reports-successful-preclinical-immunization-211000069.html
$IBIO iBio, Inc."Data on commercially available COVID-19 vaccines - all of which target the spike protein (“S protein”) - suggests that neutralizing titers are effective, but likely to wane over time. In addition, the robustness of T-cell priming and cellular immunity achieved by S protein-directed vaccines may not be sufficient to create a durable immune response, especially in the context of emerging variant strains of the virus. In contrast, the N protein gene is more conserved and stable than the spike, with 90% amino acid homology and fewer mutations over time. Notably, the SARS-CoV-2 N protein shares substantial sequence conservation with the nucleocapsid of other coronaviruses."
https://finance.yahoo.com/news/ibio-reports-successful-preclinical-immunization-211000069.html
$MJNA First to Address the United Nations About CBD
In November of 2017, Medical Marijuana, Inc. subsidiary HempMeds® Mexico became the first company to address the United Nations and the World Health Organization (W.H.O.) about cannabidiol (CBD). HempMeds® Mexico President Raul Elizalde was invited to Geneva to speak at the W.H.O Meeting of the Expert Committee on Drug Scheduling, where he urged the committee to recognize CBD as non-psychoactive and to classify it as a nutritional supplement.
https://www.medicalmarijuanainc.com/company-of-firsts/first-address-united-nations-cbd/
$MJNA First Company to Have CBD Products Listed in U.S. Physicians’ Desk Reference
$MJNA First Company to Have CBD Products Listed in U.S. Physicians’ Desk Reference
$MJNA Healthcare
Industry: Drug Manufacturers—Specialty & Generic
http://www.medicalmarijuanainc.com
CV Sciences, Inc. $CVSI http://www.cvsciences.com
Trade of the Year?
$ARFXF Current market cap is only $50M
About to launch their 'best in class' COVID serology test on June 1st
Each test kit costs $495, so if they sell 2 million tests at 25% profit, the P/E ratio would be 0.2 (versus 10-20 for the industry)
So who wants in on a potential 100-bagger?
https://covidimmunitypassport.com/product/premium-kit-covid-19-antibodies-testing/
T minus 7 days to launch!!!
$IBIO iBio on May 6 disclosed the development of IBIO-202. “In light of the successful global roll-out of COVID-19 vaccines targeting the S protein and the emergence of variant strains of the disease, we decided to focus our efforts on the continued development of IBIO-202 as a differentiated vaccine candidate,” stated Tom Isett, iBio’s chairman and CEO. https://www.genengnews.com/covid-19-candidates/ibio-ibio-202/
$IBIO “Immunization with more conserved sequences, such as the N protein, is expected to generate T-cells that could clear spike protein variant viruses in addition to the original virus,” said Martin Brenner, DVM. Ph.D., iBio’s CSO. “The N protein strategy of IBIO-202 is complementary to existing first-generation, S protein-directed vaccines and may be suitable as a more universal coronavirus vaccine.”
$IBIO Using its plant-based FastPharming® System, iBio has successfully expressed N protein antigens and has initiated both intramuscular and intranasal preclinical studies to identify favorable antigen-adjuvant combinations. Results are expected in early Q1 FY2022. iBio recently filed four provisional patent applications with the U.S. Patent and Trademark Office in support of the IBIO-202 program.
$IBIO The Company recently reported on development of IBIO-202, a subunit vaccine candidate that targets the nucleocapsid protein (“N protein”) of SARS-CoV-2. N proteins of many coronaviruses are highly immunogenic and are expressed abundantly during infection. In addition, the N protein is more highly conserved than the S protein, and therefore new viral variants may be less likely to escape vaccine protection.
"In light of the successful global roll-out of COVID-19 vaccines targeting the S protein and the emergence of variant strains of the disease, we decided to focus our efforts on the continued development of IBIO-202 as a differentiated vaccine candidate,” commented Mr. Isett. “The COVID-19 vaccine space remains highly competitive, with multiple approved vaccines in use in many countries. Nevertheless, various unmet needs remain, including: vaccines that provide broader protection against variants; the potential requirement for annual vaccine boosters; vaccines that do not require significant cold chain management; vaccines with alternative routes of administration; pan-coronavirus vaccines; and wider vaccine availability in developing countries," said Mr. Isett.
https://ir.ibioinc.com/news-events/press-releases/detail/157/ibio-reports-successful-covid-19-vaccine-toxicology-study
Press release 6 May 2021 Brussels - Coronavirus: Commission proposes EU Strategy for the development and availability of therapeutics
https://ec.europa.eu/commission/presscorner/detail/en/ip_21_2201?fbclid=IwAR2YUzo8Lu77hdl6eMR71QI5Q0c7HVjo55yfTbTZLVtT1szGQ2thgXV8P4A
$RLFTF Dr Javitt on Fox Business
Video here: https://streamable.com/dwb2fy
$RLFTF Bloomberg (Covid-19) NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure
https://www.bloomberg.com/press-releases/2021-02-23/neurorx-announces-that-zyesami-aviptadil-has-successfully-demonstrated-10-day-accelerated-recovery-from-respiratory-failur
SLEEPER ALERT!!!
LHDX just IPO'ed yesterday and they have their EUA from the FDA. They make at home covid test kits.
With the implementation of the Defense Production Act, this company should benefit, especially since the government is seeking 6 at-home covid test suppliers.
"Manning said the federal government is also using the DPA to increase the supply of at-home, rapid COVID-19 tests by bringing on six new suppliers that’ll be able to deliver 61 million tests by the end of the summer."
https://nypost.com/2021/02/05/white-house-announces-plans-to-use-defense-production-act/
https://www.barrons.com/articles/biotech-stocks-ipos-vor-bolt-lucira-immunocore-51612549141?siteid=yhoof2
https://www.businesswire.com/news/home/20210204006199/en/Lucira-Health-Announces-Pricing-of-Its-Upsized-Initial-Public-Offering
CYDY Covid play-courtsey of youssef: CytoDyn has one of the sexiest stories on the street. Friday, after the bell the company announced the initiation of sales in the Philippines. For years the shorts have been clamoring about no revenue and it looks like CytoDyn’s CEO finally took away their favorite piece of candy. This was only one part of the news, the other part was the shocking announcement that 100,000 doses of the drug was to be reserved for the Philippines and their partner Chiral Pharma Corp. The Manilla Times picked up on the story. There are currently only 250,000 doses ready to be shipped out of Samsung South Korea. This news puts the United States FDA in a pressure situation to approve the drug. In a webinar last week some of the country’s top doctors and regulators in the Philippines were educated on the Compassionate Special Permit (CSP) for leronlimab. CytoDyn also hinted that this was a stepping stone to an EUA and ultimately an approval in the philippines. The idea is that these compassionate use patients would fit the CD12 enrollment criteria for the extension trial and help get more data on the drug. The CEO Nader Pourhassen said
$SBFM: Sunshine Biopharma Receives Fourth Tranche From Previously Announced $2,000,000 + Financing for Coronavirus Treatment
MONTREAL, QC / ACCESSWIRE / January 14, 2021 / Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received the fourth tranche of funding under the recently announced committed minimum financing of $2,000,000 with RB Capital Partners Inc. This brings the total to $1,050,000 that the Company has received to date under this financing. The proceeds will be used for the ongoing development of the Company's Coronavirus Treatment on a priority basis and the clinical development of Adva-27a, the Company's flagship anticancer compound targeted for pancreatic cancer.
https://www.accesswire.com/users/newswire/images/624274/SUNSHINEBIO-LOGO111820.jpg
Sunshine Biopharma Inc. CFO, Camille Sebaaly stated, "As a company, we continue to forge forward in our development of a COVID treatment and our anticancer compounds. This investment capital has been integral to our progress in each of these sectors."
Brett Rosen and Deborah Braun of RB Capital Partners Inc. stated, "We are very impressed with the Sunshine leadership team and their commitment to developing critical life-saving medical treatments. Our investment money has been met with ongoing milestones and we are pleased to be considered a long-term funding partner of the Company. We are looking forward to a potential up-list to the Nasdaq in the future."
About Sunshine Biopharma's Coronavirus Treatment
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 1.9 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine Biopharma filed a provisional patent application for several molecules which were designed by computer-aided modeling to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to multiply. Sunshine Biopharma has since completed the synthesis of four such molecules and identified a lead compound, SBFM-PL4. In collaboration with the University of Georgia, College of Pharmacy, the Company is currently advancing the development of SBFM-PL4 through the in vitro testing stage to be followed by mice studies before entering clinical trials on COVID-19 patients.
About Sunshine Biopharma
In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.
Safe Harbor Forward-Looking Statements
This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
http://www.sunshinebiopharma.com
SOURCE: Sunshine Biopharma Inc.
View source version on accesswire.com:
https://www.accesswire.com/624274/Sunshine-Biopharma-Receives-Fourth-Tranche-From-Previously-Announced-2000000-Financing-for-Coronavirus-Treatment
What’s everyone thoughts on APT.
I’ve been watching them for a few months now and they are a PPE
Manufacturer. They will be reporting next month and based on previous reporting they have done well.
Also with potential new mask mandates and spiking cases could they be a good play?
$RLFTF (related) We are pleased to announce the inclusion of ZYESAMI™ (RLF-100™: aviptadil) in the I-SPY COVID-19 Trial which will allow us to gather data on the use of inhaled aviptadil for Critical #COVID19.
Learn more: https://prn.to/2XB5QfC
We are pleased to announce the inclusion of ZYESAMI™ (RLF-100™: aviptadil) in the I-SPY COVID-19 Trial which will allow us to gather data on the use of inhaled aviptadil for Critical #COVID19.
— NRx Pharmaceuticals (@NRxPharma) January 12, 2021
Learn more: https://t.co/xGrP7FsWsm pic.twitter.com/a9d9Xcq7wN
Achiko AG: The One Ecosystem that Takes a ‘Swiss Cheese’ Approach to COVID-19
Great article on an upcoming testing technology:
https://sponsored.bloomberg.com/news/sponsors/features/next-tech-stock/the-next-big-thing-in-health-tech/?adv=33197&prx_t=wmcGAAAAAAUk0NA&prx_ro=s&sref=GS2dzBte
SLEEPER ALERT!!!
I have a sleeper to share; and it's only a matter of time before it blows up. It has a low float and they recently got their EUA from the FDA; they got their CE mark in October, and they were peer reviewed in the Science Journal.
RNLX
RNLX, in partnership with Kantaro Biosciences has the first and only digital readout Covid tests for antibodies. Their test goes beyond a simple "positive", "negative" result but gives accurate numbers. Read more for yourself. Good luck.
https://finance.yahoo.com/news/kantaro-receives-fda-emergency-authorization-123000381.html
$RLFTF (related) copy by frenchman yhoobrd - Many of us here have been lambasting the FDA for their delay tactics- word is starting to spread:
“FDA regulators are wasting precious time in greenlighting a COVID vaccine as more than 2,000 Americans are dying each day and the pandemic continues to starve American society.
Pfizer submitted data detailing the safety and effectiveness of its vaccine on Nov. 22. But rather than immediately convening experts, the FDA scheduled a review meeting on Dec. 10, almost three weeks later. As Pfizer’s application sits on the shelf at the FDA awaiting authorization, about 27,000 Americans will have died. So what is the FDA doing for three weeks?
As a Johns Hopkins scientist who has conducted more than 100 clinical studies and reviewed thousands more from the scientific community at large, I can assure you that the agency’s review can be done within 24 to 48 hours without cutting any corners. They just need to work harder.
Contrary to popular belief, the FDA process is not hands-on—it does not interview vaccine trial patients or look under a microscope at the immune cells. It’s doing a statistical analysis and looking at data. For the vaccine trial, the data set is small and straightforward. If my research team, normally tasked with analyzing data on millions of patients, was asked to review the smaller Pfizer vaccine study of 43,000 patients, it would take about one hour.
The FDA also reviews manufacturing data from Pfizer on how they made the drug. But not only can that data be reviewed in a few hours, it should have been done months ago when it was available. While the FDA was waiting for Pfizer’s long-term vaccine results to come in, the agency should have anticipated this step and done it early.
The final step of the FDA review is to look at the outcomes of the study volunteers, including rates and severity of infection and side effects in the vaccine and placebo groups. Again, there is no plausible reason why this basic analysis cannot be done in 24 hours. The FDA and external scientists have a simple task: confirm or reject the review already conducted by the trial’s independent data safety monitoring board before FDA submission.
Let me be clear: The agency should not cut any corners in its review process, just cut out the sitting-around time. FDA insiders say the agency and its approximately 17,000 employees were dark for the four-day Thanksgiving holiday, including those working on the vaccine approval. It’s time the FDA adopts a sense of urgency. We’ve had Operation Warp Speed in developing vaccines but Operation Turtle Speed in reviewing the results...”
https://thedispatch.com/p/fda-career-staff-are-delaying-the
- some replies -
Zaran
thank you, sorry state we are in
m
@Bridge for future reference I would just have someone focus on the most efficacious of the two which is RLF-100, right? I don’t known if leronlimab is putting out numbers that are overall better than Aviptadil.
Bridge
I tweeted to Dr. Makary, responding to an earlier tweet of his. I know it’s probably useless, and after all what could he do? But I find myself sending out a tweet every few days to someone who may be able to raise these concerns. Maybe better than just watching this nightmarish delay, which makes so little sense.
Read your article re FDA vaccine delay. Same with COVID TREATMENTS like #Leronlimab and #Aviptadil
- In trials since April/May
- MOA against COVID is known
- Qualify for EUA: are SAFE and without doubt “may be” effective
- FDA is taking so long while so many die
- Can you help?
m
Dr. Marty should have focused on RLF-100 and it’s slow progress because it has a known safety profile whereas vaccines are not as well known. Pushing out RLF-100 in the 10’s of millions this December would have done more than the vaccines will. I could be wrong but would love to learn why.
Bridge
Thanks for posting. What an indictment! And that’s just the vaccines. We all knew it didn’t make sense that viable treatments like RLF-100 and leronlimab are still sitting on the shelf.
What the hell is going on? I don’t think it can be corruption like big pharma money. No half-way normal person would allow tens of thousands of deaths for money. It must be some combination of things like human complacency and stupidity. It’s hard to witness this nightmare.
crymeariver
They should focus on saving dying people instead of vaccinating healthy people.
frenchman
@BigGator There doesn’t seem to be a sense of urgency - the question is why?
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |